The GALNT1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the GALNT1 gene has been disrupted to abolish its enzymatic activity. This loss-of-function model eliminates the transfer of N-acetylgalactosamine (GalNAc) to serine/threonine residues, thereby abrogating the initial step of mucin-type O-glycosylation. The polyclonal population provides a heterogeneous pool of knockout cells, ideal for studying bulk glycophenotypic alterations without single-cell clonal biases.
Raji cells are an Epstein?CBarr virus (EBV)-positive lymphoblastoid cell line derived from a Burkitt??s lymphoma patient. As B lymphocytes, they express surface immunoglobulins and adhesion molecules that undergo extensive O-glycosylation, making them a well-characterized model for B-cell biology, lymphoma pathobiology, and glycoproteomics. Their robust proliferation and expression of relevant glycogenes provide a reproducible platform for evaluating glycosylation-dependent functions.
GALNT1 catalyzes the transfer of GalNAc to serine/threonine residues on nascent glycoproteins, initiating mucin-type O-glycosylation. Its activity is modulated by upstream factors including the SP1 transcription factor, ER stress sensors, and various protein kinase signaling cascades. Downstream targets such as MUC1, CD44, and integrins depend on GALNT1-mediated modification for proper folding, trafficking, and function. In the Golgi, GALNT1 cooperates with the C1GALT1/COSMC complex and other glycosyltransferases like ST6GALNAC1 and B3GNT6 to elaborate O-glycan structures. This stepwise glycosylation directly influences protein stability, receptor activation, and cell?Ccell interaction networks.
In Raji B lymphocytes, GALNT1 disruption leads to a truncated O-glycan repertoire, markedly affecting the glycosylation of surface receptors such as CD44 and MUC1. Consequently, cell adhesion, migration, and antigen presentation are impaired, altering interactions with lectins, extracellular matrix components, and immune effector cells. This model recapitulates aberrant glycosylation patterns observed in B-cell lymphomas and congenital disorders of glycosylation, enabling dissection of how O-glycan deficiency disturbs humoral immunity and lymphoma progression.
Researchers can employ this knockout model in lectin blotting with Vicia villosa lectin (VVL) or peanut agglutinin (PNA) to detect mucin-type O-glycans, flow cytometry to profile cell surface glycosylation changes, and mass spectrometry for detailed O-glycome analysis. Functional assays including proliferation, apoptosis, adhesion, and migration provide insights into glycosylation-dependent signaling. Applications span glycobiology, cancer-associated glycosylation studies, validation of immunotherapeutic targets, and investigation of B-cell lymphoma pathology. For further technical information, please contact Ascent Research.
